ESLA Estrella Immunopharma, Inc.
USHealthcareAs of 2026-07-10 16:00
Why ESLA matters now
Estrella Immunopharma, Inc. (ESLA) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.93 with -2.47% on the session and $39.9M in market capitalization; recent performance reads 1-month -16.67% and YTD -39.10%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-2.3M, and EPS of $-0.05. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -19.6%.
The latest indexable market news headline is "Estrella Immunopharma to Participate in the D. Boral Capital Global Conference" from Business Wire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—; recent insider activity includes Xu Jiandong filing P-Purchase. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
-7.59
P/S
0.00
EV/EBITDA
-2.94
DCF Value
$0.02
FCF Yield
-19.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
167.9%
ROA
-362.3%
ROIC
251.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-2.3M | $-0.05 |
| Q4 2025 | $0.00 | $-613.2K | $-0.02 |
| FY 2025 | $0.00 | $-13.1M | $-0.35 |
| Q3 2025 | $0.00 | $-4.8M | $-0.13 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.85
Estrella Immunopharma, Inc. is an early-stage biopharmaceutical enterprise focused on creating T-cell therapies for various blood cancers and solid tumors, with its primary activities centered in the United States. The company's lead investigational drugs include EB103, which is in preclinical development for diffuse large B-cell lymphoma, and EB104, intended for the treatment of both diffuse large B-cell lymphoma and acute lymphocytic leukemia. Estrella also maintains a collaborative agreement with Imugene Limited, working together to develop solid tumor therapies that integrate Imugene's CF33-CD19t product candidate with Estrella's EB103. The company is based in Emeryville, California.